Analysis Suggests That The \'Highly Efficient\' Pfizer Vaccine Decreases The Spread Of Coronavirus

Publish Date : 2021-02-22

According to recorded data from Israel, the Covid-19 vaccine developed by Pfizer and BioNTech appears to be highly successful in restricting the spread of the virus in a development that could change the direction of the pandemic. A research performed by Pfizer and the Israeli Ministry of Health shows that, whether symptomatic or not, the vaccine is 89.4 percent effective in preventing infections. The findings have not yet been officially published or peer reviewed, but are from a recent draught publication. The results, taken from Israel's ongoing implementation of vaccines, offer the first real-world evidence that immunization is likely to curb the spread of the virus.

Prior studies from Israel and everywhere else has already said that Covid-19 vaccines are effective in avoiding serious illness, hospital admission, and virus deaths. But a decline in the spread of Sars-CoV-2, the virus that triggers Covid-19, gives hope that by the summer the acute period of the pandemic will be brought to an end. With its inoculation programme, Israel is leading the way, providing at least one dose of the Pfizer/BioNTech jab to almost half of its population. The country's most recent report - others have similarly highlighted the vaccine's efficacy - was performed in the three weeks up to 6 February. During this period, 27.4% of individuals aged 15 and over were fully immunized using two doses of the Pfizer jab, the only Covid-19 jab available at that time. For those admitted to hospital in a serious or critical condition during the study, 4.4% had received all vaccines and 5.7% were fully vaccinated for those who died of the disease.